Atrial Fibrillation

A 55-year-old woman presents with sudden-onset palpitations that began 30 minutes earlier. She describes a sensation of rapid heartbeats with lightheadedness and dizziness but denies chest pain, dyspnea, or syncope. She has experienced similar self-resolving episodes previously and has a history of coronary artery disease. Her pulse is 180 beats/min, blood pressure is 110/70 mm Hg, respiratory rate is 16 breaths/min, oxygen saturation is 96% on room air, and temperature is 98.2°F. Laboratory studies are within normal limits. ECG demonstrates an irregularly irregular rhythm, absent discrete P waves, and narrow QRS complexes. Transesophageal echocardiography demonstrates a left atrial thrombus. Diagnosis?

The diagnosis is atrial fibrillation with rapid ventricular response and a left atrial thrombus. Her history of recurrent self-terminating episodes strongly suggests paroxysmal atrial fibrillation.

1. Definition

Atrial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by rapid, disorganized atrial electrical activity, resulting in ineffective atrial contraction and an irregularly irregular ventricular response.

When the ventricular rate is markedly elevated, as in this patient at approximately 180 beats/min, the presentation is termed atrial fibrillation with rapid ventricular response (AF with RVR).

2. Contemporary AF Classification

The 2023 ACC/AHA/ACCP/HRS guideline conceptualizes AF as a disease continuum:

1.      Stage 1: At risk for AF

o    Risk factors for AF are present without structural or electrical evidence of AF

2.      Stage 2: Pre-AF

o    Structural or electrical abnormalities predispose to AF, but clinical AF has not yet occurred

3.      Stage 3A: Paroxysmal AF

o    Intermittent AF that terminates within ≤7 days

4.      Stage 3B: Persistent AF

o    Continuous AF lasting >7 days and requiring intervention

5.      Stage 3C: Long-standing persistent AF

o    Continuous AF lasting >12 months

6.      Stage 3D: Successful AF ablation

o    Freedom from AF after catheter or surgical ablation

7.      Stage 4: Permanent AF

o    Patient and clinician have jointly decided not to pursue further rhythm-control attempts

This patient's recurrent self-terminating episodes strongly suggest paroxysmal AF, although prior episodes would ideally be documented electrocardiographically.

3. Etiology and Risk Factors

Important conditions associated with AF include:

1.      Hypertension

2.      Coronary artery disease and previous myocardial infarction

3.      Heart failure

4.      Valvular heart disease, particularly mitral valve disease

5.      Increasing age

6.      Obesity

7.      Obstructive sleep apnea

8.      Diabetes mellitus

9.      Hyperthyroidism

10.  Excessive alcohol consumption

11.  Chronic kidney disease

12.  Atrial enlargement and other structural heart disease

4. Pathophysiology

1.      AF develops through interaction between electrical triggers and an abnormal atrial substrate

2.      Ectopic electrical activity frequently arises near the pulmonary veins

3.      Atrial remodeling, fibrosis, inflammation, and conduction abnormalities promote maintenance of AF

4.      Rapid disorganized atrial activation causes loss of coordinated atrial contraction

5.      Variable conduction through the AV node produces an irregularly irregular ventricular rhythm

6.      Loss of effective atrial contraction promotes blood stasis, particularly within the left atrial appendage

7.      Blood stasis, endothelial abnormalities, and a prothrombotic state promote left atrial or left atrial appendage thrombus formation

8.      Thrombus embolization may cause:

o    Ischemic stroke

o    Systemic arterial embolism

5. Clinical Features

AF may cause:

1.      Palpitations

2.      Lightheadedness or dizziness

3.      Fatigue

4.      Dyspnea

5.      Reduced exercise tolerance

6.      Chest discomfort

7.      Presyncope or syncope in severe cases

8.      Some patients remain asymptomatic

Hemodynamic compromise may occur when the ventricular response is very rapid or when significant underlying cardiac disease is present.

6. Diagnosis

6.1 Electrocardiography

Characteristic ECG findings include:

1.      Irregularly irregular RR intervals

2.      Absence of discrete P waves

3.      Fibrillatory atrial activity may be visible

4.      QRS complexes are usually narrow unless there is:

o    Bundle-branch block

o    Ventricular aberrancy

o    Pre-excitation

In this patient, a ventricular rate of approximately 180 beats/min indicates AF with rapid ventricular response.

6.2 Echocardiography

1.      Transthoracic echocardiography evaluates:

o    Left ventricular function

o    Left atrial size

o    Valvular disease

o    Other structural heart disease

2.      Transesophageal echocardiography (TEE) provides superior visualization of the left atrium and left atrial appendage

3.      TEE is particularly useful for identifying intracardiac thrombus before planned cardioversion

This patient's documented left atrial thrombus substantially increases her thromboembolic risk and directly affects cardioversion management.

6.3 Laboratory Evaluation

Evaluation for reversible or contributing factors may include:

1.      Electrolytes

2.      Renal function

3.      Complete blood count

4.      Thyroid function

5.      Additional testing based on the clinical presentation

7. Management

Management incorporates:

1.      Acute ventricular rate control

2.      Stroke and systemic embolism prevention

3.      Appropriate rhythm-control strategies

4.      Treatment of underlying cardiovascular disease and modifiable risk factors

7.1 Assess Hemodynamic Stability

Signs of clinically significant instability attributable to AF include:

1.      Hypotension or shock

2.      Ongoing myocardial ischemia

3.      Acute pulmonary edema or severe heart failure

4.      Altered mental status due to poor perfusion

This patient is currently hemodynamically stable, despite her rapid ventricular rate.

If AF causes life-threatening hemodynamic instability, immediate synchronized electrical cardioversion is indicated despite the presence of thrombus, with therapeutic anticoagulation initiated as soon as clinically feasible.

7.2 Acute Rate Control

For this hemodynamically stable patient with a known atrial thrombus:

1.      Beta blockers are appropriate first-line agents in many patients

2.      Diltiazem or verapamil may be used if the left ventricular ejection fraction is >40% and there is no contraindication

3.      Digoxin may be used in selected patients when beta blockers or nondihydropyridine calcium-channel blockers are ineffective or contraindicated

4.      IV amiodarone should not be used routinely for rate control in this setting, because it may restore sinus rhythm and increase thromboembolic risk when intracardiac thrombus is present

Diltiazem and verapamil should be avoided in patients with significant left ventricular systolic dysfunction.

7.3 Cardioversion and the Left Atrial Thrombus

The presence of a documented intracardiac thrombus fundamentally changes management.

1.      Planned electrical or pharmacologic cardioversion should be deferred

2.      Begin or continue therapeutic anticoagulation

3.      Under ACC/AHA guidance, repeat imaging is generally performed after 3 to 6 weeks of therapeutic anticoagulation to assess for thrombus resolution

4.      The 2024 ESC guideline recommends at least 4 weeks of therapeutic anticoagulation before repeat transesophageal imaging when intracardiac thrombus is present

5.      Repeat TEE or appropriate cardiac CT imaging should be performed to determine whether the thrombus has resolved

6.      Cardioversion may be reconsidered only after documented thrombus resolution

7.      If thrombus persists, anticoagulation should be continued and the management strategy reassessed

The fact that the symptomatic episode began only 30 minutes ago does not make elective cardioversion appropriate when a left atrial thrombus is already demonstrated.

7.4 Cardioversion in Patients Without Intracardiac Thrombus

Duration-based recommendations differ slightly between major guidelines:

1.      ACC/AHA guidance

o    If AF has been present for ≥48 hours or the duration is uncertain, patients should receive:

§  Therapeutic anticoagulation for at least 3 weeks before cardioversion, or

§  Precardioversion imaging to exclude intracardiac thrombus

2.      2024 ESC guidance

o    Uses a more conservative threshold of >24 hours

o    Cardioversion should generally be delayed until at least 3 weeks of anticoagulation have been given unless imaging excludes thrombus

3.      Anticoagulation should generally be continued for at least 4 weeks after cardioversion

4.      Recent-onset AF does not automatically imply negligible thromboembolic risk

In this patient, the documented left atrial thrombus overrides duration-based considerations, and elective cardioversion must be deferred.

7.5 Rhythm Control

Rhythm-control options include:

1.      Electrical cardioversion

2.      Antiarrhythmic drug therapy

3.      Catheter ablation

Choice depends on:

·         Symptoms

·         AF burden and duration

·         Structural heart disease

·         Coronary artery disease

·         Ventricular function

·         Patient preference

Class IC agents such as flecainide and propafenone should not be used in patients with previous myocardial infarction or significant structural heart disease and should be avoided in severe coronary artery disease. This patient's CAD history should therefore be characterized before selecting an antiarrhythmic drug.

Early rhythm-control therapy can be beneficial in appropriately selected patients with recently diagnosed AF, but this patient's atrial thrombus must first be addressed before elective cardioversion or catheter ablation.

7.6 Anticoagulation

Immediate issue

1.      A documented left atrial thrombus requires therapeutic anticoagulation, regardless of the apparent duration of the presenting AF episode or the calculated long-term stroke-risk score

Long-term stroke prevention

1.      The 2023 ACC/AHA/ACCP/HRS guideline uses validated risk assessment such as CHA₂DS₂-VASc

2.      Oral anticoagulation is recommended when estimated annual thromboembolic risk is ≥2% per year, approximately corresponding to:

o    CHA₂DS₂-VASc ≥2 in men

o    CHA₂DS₂-VASc ≥3 in women

3.      Anticoagulation is reasonable at intermediate risk, approximately:

o    CHA₂DS₂-VASc 1 in men

o    CHA₂DS₂-VASc 2 in women

4.      The 2024 ESC guideline uses CHA₂DS₂-VA, which excludes sex as an independent point:

o    Score ≥2: oral anticoagulation recommended

o    Score 1: oral anticoagulation should be considered

Patient-specific risk assessment

1.      This patient's coronary artery disease counts as vascular disease

2.      Her CHA₂DS₂-VASc score is 2

o    Vascular disease = 1

o    Female sex = 1

o    Under ACC/AHA guidance, long-term anticoagulation is reasonable

3.      Her CHA₂DS₂-VA score is 1

o    Vascular disease = 1

o    Under ESC guidance, long-term anticoagulation should be considered

4.      These long-term risk scores do not alter the immediate management because the existing left atrial thrombus independently mandates therapeutic anticoagulation

Choice of anticoagulant

1.      Direct oral anticoagulants (DOACs) are preferred over warfarin in eligible patients

2.      Exceptions include patients with:

o    Mechanical heart valves

o    Moderate-to-severe mitral stenosis

3.      In these patients, vitamin K antagonist therapy is recommended instead of a DOAC

Long-term anticoagulation decisions should be based on thromboembolic risk and should not depend solely on whether sinus rhythm is subsequently restored.

7.7 Catheter Ablation

1.      Catheter ablation is an effective rhythm-control strategy for symptomatic AF

2.      It may be used as first-line rhythm-control therapy in selected patients, particularly those with symptomatic paroxysmal AF

3.      It is also appropriate when antiarrhythmic drugs are ineffective, contraindicated, not tolerated, or not preferred

4.      A documented left atrial thrombus is a contraindication to AF catheter ablation because instrumentation of the left atrium may dislodge the thrombus and cause systemic embolization

5.      Because this patient has a documented left atrial thrombus, catheter ablation should be deferred until therapeutic anticoagulation has been given and repeat imaging confirms thrombus resolution

7.8 Left Atrial Appendage Occlusion

Percutaneous left atrial appendage occlusion may be considered in selected patients who:

1.      Have clinically significant thromboembolic risk, and

2.      Have a contraindication to long-term oral anticoagulation or, in selected circumstances, a high bleeding risk that makes long-term anticoagulation undesirable

It is not routinely preferred over oral anticoagulation in patients who can safely receive anticoagulant therapy.

7.9 Risk-Factor Modification

Long-term AF management should also address:

1.      Hypertension

2.      Obesity

3.      Obstructive sleep apnea

4.      Diabetes

5.      Physical inactivity

6.      Excessive alcohol intake

7.      Smoking

8.      Other cardiovascular disease

8. Complications

1.      Ischemic stroke

2.      Systemic arterial embolism

3.      Heart failure

4.      Tachycardia-induced cardiomyopathy

5.      Myocardial ischemia in susceptible patients

6.      Recurrent hospitalization and impaired quality of life

9. Key Clinical Insight

An irregularly irregular narrow-complex tachycardia with absent discrete P waves is characteristic of atrial fibrillation. In this patient, a ventricular rate of 180 beats/min indicates AF with RVR, while the documented left atrial thrombus mandates therapeutic anticoagulation and postponement of elective cardioversion and catheter ablation until adequate anticoagulation has been given and repeat imaging confirms thrombus resolution.

References

1.      Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149(1):e1-e156. doi:10.1161/CIR.0000000000001193.

2.      Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi:10.1093/eurheartj/ehae176. Corrected in 2025; doi:10.1093/eurheartj/ehaf306.

3.      Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-1316. doi:10.1056/NEJMoa2019422.